Bristol-Myers Squibb Company (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$59.43
-$0.69(-1.21%)
At close: 4:00 PM EST
$59.43
-$0.69(-1.21%)
Day’s Range― - ―
52-Week Range$42.52 - $62.89
Previous CloseN/A
Volume3.98M
Average Volume (3M)13.50M
Market Cap
$121.03B
Enterprise Value$157.96B
Total Cash (Recent Filing)$10.67B
Total Debt (Recent Filing)$47.14B
Price to Earnings (P/E)15.6
Beta0.30
Next Earnings
Apr 30, 2026EPS Estimate
1.45Next Dividend Ex-DateN/A
Dividend Yield4.84%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,036,473,800
10 Day Avg. Volume16,467,334
30 Day Avg. Volume13,496,934
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.28
Enterprise Value/Gross Profit4.85
Enterprise Value/Ebitda10.86
Forecast
1Y Price Target
$62.67Price Target Upside5.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)6.26
Revenue Forecast (FY)$46.91B
Bulls Say, Bears Say
Bulls Say
CELMoD Clinical ValidationPhase III results showing higher rates of minimal residual disease negativity for iberdomide combined with standard therapy support the CELMoD class as a potential long-term growth driver in multiple myeloma.
Eliquis Pricing And GuidanceOne-time U.S. pricing changes that removed accumulated rebates and certain penalties improved revenue visibility for the leading anticoagulant and underpinned guidance that exceeded consensus.
New Product Launches And Pipeline DepthA broad clinical portfolio with multiple early commercial launches and growth-stage products gaining market traction could help replace revenue from brands facing patent pressure and support future top-line growth.
Bears Say
Generic Competition And Revenue ErosionImminent loss of exclusivity for key medicines and expected generic entry pose a clear risk of substantial revenue decline for the company over time.
Iberdomide Safety And TolerabilitySelection of the lowest iberdomide dose and earlier reports of neutropenia raise concern that tolerability issues could limit dosing options and patient uptake.
Regulatory Evidence And Approval RiskFinal overall survival data and outcomes of regulatory review remain unresolved, creating uncertainty about conversion from accelerated to full approvals and ultimate commercial impact.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $42.52 and its highest was $62.89 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $121.03B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Apr 30, 2026 which is in 34 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Feb 05, 2026. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.226 by $0.034.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Undervalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.84%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.45.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,036,473,800 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $1.26 in its last earnings report, beating expectations of $1.226. Following the earnings report the stock price went up 3.297%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.67 (5.45% Upside)
$62.67 (5.45% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Bullish
Bullish news 79%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.44%
12-Months-Change
Fundamentals
Return on Equity
39.27%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Company Deck
BMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$62.67
▲(5.45% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
19.16% Mutual Funds
14.39% Other Institutional Investors
38.83% Public Companies and Individual Investors